{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T06:05:21Z","timestamp":1760853921467},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,10,5]],"date-time":"2016-10-05T00:00:00Z","timestamp":1475625600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2016,10,5]],"date-time":"2016-10-05T00:00:00Z","timestamp":1475625600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Direct-acting antivirals (DAAs) for hepatitis C virus (HCV) have potent anti-HCV effects but may provoke resistance-associated variants (RAVs). In this study, we assessed the characteristics of these RAVs and explored efficacious anti-HCV reagents using recombinant HCV with NS5A from a genotype 1b strain. We replaced the NS5A of JFH1 with that of Con1 (JFH1\/5ACon1) and introduced known NS5A inhibitor resistance mutations (L31M, L31V, L31I and Y93H) individually or in combination. Susceptibilities against anti-HCV reagents were also investigated. RAVs with Y93H exhibited high extracellular core antigen levels and infectivity titers. Variants with any single mutation showed mild to moderate resistance against NS5A inhibitors, whereas variants with double mutations at both L31 and Y93 showed severe resistance. The variants with mutations exhibited similar levels of susceptibility to interferon (IFN)-\u03b1, IFN-\u03bb1, IFN-\u03bb3 and Ribavirin. Variants with the Y93H mutation were more sensitive to protease inhibitors compared with JFH1\/5ACon1. In conclusion, the <jats:italic>in vitro<\/jats:italic> analysis indicated that the Y93H mutation enhanced infectious virus production, suggesting advantages in the propagation of RAVs with this mutation. However, these RAVs were susceptible to protease inhibitors. Thus, a therapeutic regimen that includes these reagents is a promising means to eradicate these RAVs.<\/jats:p>","DOI":"10.1038\/srep34652","type":"journal-article","created":{"date-parts":[[2016,10,5]],"date-time":"2016-10-05T09:20:54Z","timestamp":1475659254000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Effects of Resistance-Associated NS5A Mutations in Hepatitis C Virus on Viral Production and Susceptibility to Antiviral Reagents"],"prefix":"10.1038","volume":"6","author":[{"given":"Sayuri","family":"Nitta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhiro","family":"Asahina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mami","family":"Matsuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norie","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryuichi","family":"Sugiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Masaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryosuke","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuyuki","family":"Kato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mamoru","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takaji","family":"Wakita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takanobu","family":"Kato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,10,5]]},"reference":[{"key":"BFsrep34652_CR1","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1016\/S0140-6736(14)62401-6","volume":"385","author":"DP Webster","year":"2015","unstructured":"Webster, D. P., Klenerman, P. & Dusheiko, G. M. Hepatitis C. The Lancet 385, 1124\u20131135, doi: 10.1016\/S0140-6736(14)62401-6 (2015).","journal-title":"The Lancet"},{"key":"BFsrep34652_CR2","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1136\/gutjnl-2015-310421","volume":"64","author":"F Zoulim","year":"2015","unstructured":"Zoulim, F. et al. Hepatitis C virus treatment in the real world: optimising treatment and access to therapies. Gut 64, 1824\u20131833, doi: 10.1136\/gutjnl-2015-310421 (2015).","journal-title":"Gut"},{"key":"BFsrep34652_CR3","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1053\/j.gastro.2014.03.003","volume":"146","author":"JM Pawlotsky","year":"2014","unstructured":"Pawlotsky, J. M. New Hepatitis C Therapies: The Toolbox, Strategies, and Challenges. Gastroenterology 146, 1176\u20131192, doi: 10.1053\/j.gastro.2014.03.003 (2014).","journal-title":"Gastroenterology"},{"key":"BFsrep34652_CR4","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.jhep.2013.03.030","volume":"59","author":"JM Pawlotsky","year":"2013","unstructured":"Pawlotsky, J. M. NS5A inhibitors in the treatment of hepatitis C. J Hepatol 59, 375\u2013382, doi: 10.1016\/j.jhep.2013.03.030 (2013).","journal-title":"J Hepatol"},{"key":"BFsrep34652_CR5","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/j.jhep.2015.09.011","volume":"64","author":"C Sarrazin","year":"2016","unstructured":"Sarrazin, C. The importance of resistance to direct antiviral drugs in HCV infection in clinical practice. Journal of Hepatology 64, 486\u2013504, doi: 10.1016\/j.jhep.2015.09.011 (2016).","journal-title":"Journal of Hepatology"},{"key":"BFsrep34652_CR6","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1016\/j.jhep.2015.08.010","volume":"63","author":"M Buti","year":"2015","unstructured":"Buti, M., Riveiro-Barciela, M. & Esteban, R. Management of direct-acting antiviral agent failures. Journal of Hepatology 63, 1511\u20131522, doi: 10.1016\/j.jhep.2015.08.010 (2015).","journal-title":"Journal of Hepatology"},{"key":"BFsrep34652_CR7","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1002\/hep.27934","volume":"62","author":"E Lontok","year":"2015","unstructured":"Lontok, E. et al. Hepatitis C virus drug resistance\u2013associated substitutions: State of the art summary. Hepatology 62, 1623\u20131632, doi: 10.1002\/hep.27934 (2015).","journal-title":"Hepatology"},{"key":"BFsrep34652_CR8","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1038\/nature08960","volume":"465","author":"M Gao","year":"2010","unstructured":"Gao, M. et al. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature 465, 96\u2013100, doi: 10.1038\/nature08960 (2010).","journal-title":"Nature"},{"key":"BFsrep34652_CR9","doi-asserted-by":"publisher","first-page":"2054","DOI":"10.1128\/AAC.02494-12","volume":"57","author":"C Wang","year":"2013","unstructured":"Wang, C. et al. Persistence of resistant variants in hepatitis C virus-infected patients treated with the NS5A replication complex inhibitor daclatasvir. Antimicrob Agents Chemother 57, 2054\u20132065, doi: 10.1128\/AAC.02494-12 (2013).","journal-title":"Antimicrob Agents Chemother"},{"key":"BFsrep34652_CR10","doi-asserted-by":"publisher","first-page":"3641","DOI":"10.1128\/AAC.00556-10","volume":"54","author":"RA Fridell","year":"2010","unstructured":"Fridell, R. A., Qiu, D., Wang, C., Valera, L. & Gao, M. Resistance analysis of the hepatitis C virus NS5A inhibitor BMS-790052 in an in vitro replicon system. Antimicrob Agents Chemother 54, 3641\u20133650, doi: 10.1128\/AAC.00556-10 (2010).","journal-title":"Antimicrob Agents Chemother"},{"key":"BFsrep34652_CR11","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1053\/j.gastro.2010.11.036","volume":"140","author":"TK Scheel","year":"2011","unstructured":"Scheel, T. K., Gottwein, J. M., Mikkelsen, L. S., Jensen, T. B. & Bukh, J. Recombinant HCV variants with NS5A from genotypes 1-7 have different sensitivities to an NS5A inhibitor but not interferon-alpha. Gastroenterology 140, 1032\u20131042, doi: 10.1053\/j.gastro.2010.11.036 (2011).","journal-title":"Gastroenterology"},{"key":"BFsrep34652_CR12","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.jcv.2012.04.024","volume":"54","author":"F Suzuki","year":"2012","unstructured":"Suzuki, F. et al. Prevalence of hepatitis C virus variants resistant to NS3 protease inhibitors or the NS5A inhibitor (BMS-790052) in hepatitis patients with genotype 1b. J Clin Virol 54, 352\u2013354, doi: 10.1016\/j.jcv.2012.04.024 (2012).","journal-title":"J Clin Virol"},{"key":"BFsrep34652_CR13","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1002\/hep.27113","volume":"59","author":"H Kumada","year":"2014","unstructured":"Kumada, H. et al. Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. Hepatology 59, 2083\u20132091, doi: 10.1002\/hep.27113 (2014).","journal-title":"Hepatology"},{"key":"BFsrep34652_CR14","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.jhep.2012.11.012","volume":"58","author":"Y Karino","year":"2013","unstructured":"Karino, Y. et al. Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir. J Hepatol 58, 646\u2013654, doi: 10.1016\/j.jhep.2012.11.012 (2013).","journal-title":"J Hepatol"},{"key":"BFsrep34652_CR15","doi-asserted-by":"crossref","unstructured":"Miura, M. et al. Deep sequencing analysis of variants resistant to the non-structural 5A inhibitor daclatasvir in patients with genotype 1b hepatitis C virus infection. Hepatol Res, doi: 10.1111\/hepr.12316 (2014).","DOI":"10.1111\/hepr.12316"},{"key":"BFsrep34652_CR16","doi-asserted-by":"crossref","unstructured":"Manns, M. et al. All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study. Lancet, doi: 10.1016\/S0140-6736(14)61059-X (2014).","DOI":"10.1016\/S0140-6736(14)61059-X"},{"key":"BFsrep34652_CR17","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1002\/jmv.24255","volume":"87","author":"S Yoshimi","year":"2015","unstructured":"Yoshimi, S. et al. Long term persistence of NS5A inhibitor-resistant hepatitis C virus in patients who failed daclatasvir and asunaprevir therapy. Journal of Medical Virology 87, 1913\u20131920, doi: 10.1002\/jmv.24255 (2015).","journal-title":"Journal of Medical Virology"},{"key":"BFsrep34652_CR18","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1002\/hep.26388","volume":"58","author":"F McPhee","year":"2013","unstructured":"McPhee, F. et al. Resistance analysis of hepatitis C virus genotype 1 prior treatment null responders receiving daclatasvir and asunaprevir. Hepatology 58, 902\u2013911, doi: 10.1002\/hep.26388 (2013).","journal-title":"Hepatology"},{"key":"BFsrep34652_CR19","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1126\/science.285.5424.110","volume":"285","author":"V Lohmann","year":"1999","unstructured":"Lohmann, V. et al. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 285, 110\u2013113 (1999).","journal-title":"Science"},{"key":"BFsrep34652_CR20","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1038\/nm1268","volume":"11","author":"T Wakita","year":"2005","unstructured":"Wakita, T. et al. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 11, 791\u2013796, doi: 10.1038\/nm1268 (2005).","journal-title":"Nat Med"},{"key":"BFsrep34652_CR21","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.bbrc.2011.05.144","volume":"410","author":"Y Okamoto","year":"2011","unstructured":"Okamoto, Y. et al. Development of recombinant hepatitis C virus with NS5A from strains of genotypes 1 and 2. Biochem Biophys Res Commun 410, 404\u2013409, doi: 10.1016\/j.bbrc.2011.05.144 (2011).","journal-title":"Biochem Biophys Res Commun"},{"key":"BFsrep34652_CR22","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1002\/hep.24399","volume":"54","author":"M Saeed","year":"2011","unstructured":"Saeed, M. et al. In vivo adaptation of hepatitis C virus in chimpanzees for efficient virus production and evasion of apoptosis. Hepatology 54, 425\u2013433, doi: 10.1002\/hep.24399 (2011).","journal-title":"Hepatology"},{"key":"BFsrep34652_CR23","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1002\/hep.25763","volume":"56","author":"T Matsumura","year":"2012","unstructured":"Matsumura, T. et al. 25-Hydroxyvitamin D3 suppresses hepatitis C virus production. Hepatology 56, 1231\u20131239, doi: 10.1002\/hep.25763 (2012).","journal-title":"Hepatology"},{"key":"BFsrep34652_CR24","doi-asserted-by":"publisher","first-page":"13994","DOI":"10.1038\/srep13994","volume":"5","author":"M Tasaka-Fujita","year":"2015","unstructured":"Tasaka-Fujita, M. et al. Amino Acid Polymorphisms in Hepatitis C Virus Core Affect Infectious Virus Production and Major Histocompatibility Complex Class I Molecule Expression. Sci Rep 5, 13994, doi: 10.1038\/srep13994 (2015).","journal-title":"Sci Rep"},{"key":"BFsrep34652_CR25","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.virusres.2009.08.006","volume":"146","author":"N Kato","year":"2009","unstructured":"Kato, N. et al. Efficient replication systems for hepatitis C virus using a new human hepatoma cell line. Virus Res 146, 41\u201350, doi: 10.1016\/j.virusres.2009.08.006 (2009).","journal-title":"Virus Res"},{"key":"BFsrep34652_CR26","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.virusres.2011.02.005","volume":"157","author":"K Mori","year":"2011","unstructured":"Mori, K. et al. Mechanism of action of ribavirin in a novel hepatitis C virus replication cell system. Virus Res 157, 61\u201370, doi: 10.1016\/j.virusres.2011.02.005 (2011).","journal-title":"Virus Res"},{"key":"BFsrep34652_CR27","doi-asserted-by":"publisher","first-page":"e0138060","DOI":"10.1371\/journal.pone.0138060","volume":"10","author":"J Itakura","year":"2015","unstructured":"Itakura, J. et al. Resistance-Associated NS5A Variants of Hepatitis C Virus Are Susceptible to Interferon-Based Therapy. PLoS One 10, e0138060 (2015).","journal-title":"PLoS One"},{"key":"BFsrep34652_CR28","doi-asserted-by":"crossref","unstructured":"Kan, T. et al. The clinical features of patients with a Y93H variant of hepatitis C virus detected by a PCR invader assay. Journal of Gastroenterology, 1\u20138, doi: 10.1007\/s00535-015-1080-1 (2015).","DOI":"10.1007\/s00535-015-1080-1"},{"key":"BFsrep34652_CR29","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1016\/j.jhep.2015.03.033","volume":"63","author":"S Akamatsu","year":"2015","unstructured":"Akamatsu, S. et al. Association between variants in the interferon lambda 4 locus and substitutions in the hepatitis C virus non-structural protein 5A. J Hepatol 63, 554\u2013563, doi: 10.1016\/j.jhep.2015.03.033 (2015).","journal-title":"J Hepatol"},{"key":"BFsrep34652_CR30","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1002\/hep.28255","volume":"63","author":"K-H Peiffer","year":"2016","unstructured":"Peiffer, K.-H. et al. IFN lambda 4 genotypes and resistance-associated variants in HCV genotype 1 and 3 infected patients. Hepatology 63, 63\u201373, doi: 10.1002\/hep.28255 (2016).","journal-title":"Hepatology"},{"key":"BFsrep34652_CR31","doi-asserted-by":"publisher","first-page":"6333","DOI":"10.1128\/AAC.02193-12","volume":"57","author":"KA Wong","year":"2013","unstructured":"Wong, K. A. et al. Characterization of Hepatitis C virus resistance from a multiple-dose clinical trial of the novel NS5A inhibitor GS-5885. Antimicrob Agents Chemother 57, 6333\u20136340, doi: 10.1128\/AAC.02193-12 (2013).","journal-title":"Antimicrob Agents Chemother"},{"key":"BFsrep34652_CR32","doi-asserted-by":"crossref","unstructured":"Cheng, G. et al. In Vitro Antiviral Activity and Resistance Profile Characterization of the HCV NS5A Inhibitor Ledipasvir. Antimicrob Agents Chemother, doi: 10.1128\/AAC.02524-15 (2016).","DOI":"10.1128\/AAC.02524-15"},{"key":"BFsrep34652_CR33","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1002\/hep.26421","volume":"58","author":"K Mori","year":"2013","unstructured":"Mori, K. et al. Adenosine kinase is a key determinant for the anti-HCV activity of ribavirin. Hepatology 58, 1236\u20131244, doi: 10.1002\/hep.26421 (2013).","journal-title":"Hepatology"},{"key":"BFsrep34652_CR34","doi-asserted-by":"publisher","first-page":"E115","DOI":"10.1111\/hepr.12474","volume":"45","author":"J Itakura","year":"2015","unstructured":"Itakura, J. et al. Naturally occurring, resistance-associated hepatitis C virus NS5A variants are linked to interleukin-28B genotype and are sensitive to interferon-based therapy. Hepatol Res 45, E115\u2013E121, doi: 10.1111\/hepr.12474 (2015).","journal-title":"Hepatol Res"},{"key":"BFsrep34652_CR35","doi-asserted-by":"publisher","first-page":"7624","DOI":"10.1128\/jvi.00724-08","volume":"82","author":"Y Ma","year":"2008","unstructured":"Ma, Y., Yates, J., Liang, Y., Lemon, S. M. & Yi, M. NS3 Helicase Domains Involved in Infectious Intracellular Hepatitis C Virus Particle Assembly. Journal of Virology 82, 7624\u20137639, doi: 10.1128\/jvi.00724-08 (2008).","journal-title":"Journal of Virology"},{"key":"BFsrep34652_CR36","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.chom.2014.10.008","volume":"16","author":"D Paul","year":"2014","unstructured":"Paul, D., Madan, V. & Bartenschlager, R. Hepatitis C Virus RNA Replication and Assembly: Living on the Fat of the Land. Cell Host & Microbe 16, 569\u2013579, doi: 10.1016\/j.chom.2014.10.008 (2014).","journal-title":"Cell Host & Microbe"},{"key":"BFsrep34652_CR37","doi-asserted-by":"publisher","first-page":"11149","DOI":"10.1074\/jbc.M111392200","volume":"277","author":"Y Shirota","year":"2002","unstructured":"Shirota, Y. et al. Hepatitis C virus (HCV) NS5A binds RNA-dependent RNA polymerase (RdRP) NS5B and modulates RNA-dependent RNA polymerase activity. J Biol Chem 277, 11149\u201311155, doi: 10.1074\/jbc.M111392200 (2002).","journal-title":"J Biol Chem"},{"key":"BFsrep34652_CR38","doi-asserted-by":"publisher","first-page":"2738","DOI":"10.1128\/JVI.78.6.2738-2748.2004","volume":"78","author":"T Shimakami","year":"2004","unstructured":"Shimakami, T. et al. Effect of interaction between hepatitis C virus NS5A and NS5B on hepatitis C virus RNA replication with the hepatitis C virus replicon. J Virol 78, 2738\u20132748 (2004).","journal-title":"J Virol"},{"key":"BFsrep34652_CR39","doi-asserted-by":"publisher","first-page":"5387","DOI":"10.1128\/AAC.01186-12","volume":"56","author":"F McPhee","year":"2012","unstructured":"McPhee, F. et al. Preclinical Profile and Characterization of the Hepatitis C Virus NS3 Protease Inhibitor Asunaprevir (BMS-650032). Antimicrob Agents Chemother 56, 5387\u20135396, doi: 10.1128\/AAC.01186-12 (2012).","journal-title":"Antimicrob Agents Chemother"},{"key":"BFsrep34652_CR40","doi-asserted-by":"publisher","first-page":"3359","DOI":"10.1128\/AAC.00054-12","volume":"56","author":"A Lam","year":"2012","unstructured":"Lam, A. et al. Genotype and subtype profiling of PSI-7977 as a nucleotide inhibitor of hepatitis C virus. Antimicrob Agents Chemother 56, 3359\u20133368 (2012).","journal-title":"Antimicrob Agents Chemother"},{"key":"BFsrep34652_CR41","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1128\/aac.01058-08","volume":"53","author":"T-I Lin","year":"2009","unstructured":"Lin, T.-I. et al. In Vitro Activity and Preclinical Profile of TMC435350, a Potent Hepatitis C Virus Protease Inhibitor. Antimicrob Agents Chemother 53, 1377\u20131385, doi: 10.1128\/aac.01058-08 (2009).","journal-title":"Antimicrob Agents Chemother"},{"key":"BFsrep34652_CR42","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1002\/hep.26660","volume":"59","author":"S Ramirez","year":"2014","unstructured":"Ramirez, S. et al. Highly efficient infectious cell culture of three hepatitis C virus genotype 2b strains and sensitivity to lead protease, nonstructural protein 5A, and polymerase inhibitors. Hepatology 59, 395\u2013407, doi: 10.1002\/hep.26660 (2014).","journal-title":"Hepatology"},{"key":"BFsrep34652_CR43","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1053\/j.gastro.2011.06.004","volume":"141","author":"JM Gottwein","year":"2011","unstructured":"Gottwein, J. M., Scheel, T. K., Jensen, T. B., Ghanem, L. & Bukh, J. Differential efficacy of protease inhibitors against HCV genotypes 2a, 3a, 5a, and 6a NS3\/4A protease recombinant viruses. Gastroenterology 141, 1067\u20131079, doi: 10.1053\/j.gastro.2011.06.004 (2011).","journal-title":"Gastroenterology"},{"key":"BFsrep34652_CR44","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1053\/j.gastro.2013.11.009","volume":"146","author":"YP Li","year":"2014","unstructured":"Li, Y. P. et al. Differential sensitivity of 5\u2019UTR-NS5A recombinants of hepatitis C virus genotypes 1-6 to protease and NS5A inhibitors. Gastroenterology 146, 812\u2013821 e814, doi: 10.1053\/j.gastro.2013.11.009 (2014).","journal-title":"Gastroenterology"},{"key":"BFsrep34652_CR45","doi-asserted-by":"publisher","first-page":"2334","DOI":"10.1038\/nprot.2006.395","volume":"1","author":"T Kato","year":"2006","unstructured":"Kato, T. et al. Cell culture and infection system for hepatitis C virus. Nat Protoc 1, 2334\u20132339, doi: 10.1038\/nprot.2006.395 (2006).","journal-title":"Nat Protoc"},{"key":"BFsrep34652_CR46","doi-asserted-by":"publisher","first-page":"2658","DOI":"10.1099\/vir.0.068528-0","volume":"95","author":"M Matsuda","year":"2014","unstructured":"Matsuda, M. et al. Alternative endocytosis pathway for productive entry of hepatitis C virus. J Gen Virol 95, 2658\u20132667, doi: 10.1099\/vir.0.068528-0 (2014).","journal-title":"J Gen Virol"},{"key":"BFsrep34652_CR47","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1128\/JCM.37.6.1802-1808.1999","volume":"37","author":"K Aoyagi","year":"1999","unstructured":"Aoyagi, K. et al. Development of a simple and highly sensitive enzyme immunoassay for hepatitis C virus core antigen. J Clin Microbiol 37, 1802\u20131808 (1999).","journal-title":"J Clin Microbiol"},{"key":"BFsrep34652_CR48","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1128\/JCM.00487-12","volume":"50","author":"A Murayama","year":"2012","unstructured":"Murayama, A. et al. Japanese reference panel of blood specimens for evaluation of hepatitis C virus RNA and core antigen quantitative assays. J Clin Microbiol 50, 1943\u20131949, doi: 10.1128\/JCM.00487-12 (2012).","journal-title":"J Clin Microbiol"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep34652.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep34652","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep34652.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T01:55:37Z","timestamp":1672883737000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep34652"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10,5]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2016,12,16]]}},"alternative-id":["BFsrep34652"],"URL":"https:\/\/doi.org\/10.1038\/srep34652","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,10,5]]},"assertion":[{"value":"26 April 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Y.A. belongs to a donation-funded department funded by Chugai Pharmaceutical Co. Ltd., Toray Industries Inc., Bristol-Myers Squibb, Dainippon Sumitomo Pharma Co. Ltd., and Merck Sharp and Dohme. M.W. has received research support from Chugai Pharmaceutical Co. Ltd., Bristol-Myers Squibb, and Merck Sharp and Dohme.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"34652"}}